ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
Dow Jones
38,834.86
0.15%
Brent Oil
84.59
-0.23%
Bitcoin
65,105.04
-0.05%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Quote

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
Add to Watchlist
3.88
0.15
(4.02%)
Closed June 19 4:00PM
Delayed by 15 minutes
3.83
-0.05
(-1.29%)
After Hours: 4:49PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.83
Bid
3.61
Ask
6.50
Volume
930,581
3.6337 Day's Range 3.89
3.25 52 Week Range 10.45
Market Cap
319.418M
Previous Close
3.73
Open
3.72
Last Trade
10
@
3.7
Last Trade Time
Financial Volume
$ 3,486,690
VWAP
3.7468
Average Volume (3m)
1,122,404
Shares Outstanding
82,112,511
Dividend Yield
-
PE Ratio
-6.72
Earnings Per Share (EPS)
-0.58
Revenue
-
Net Profit
-47.51M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.anavex.com
Headquarters
Carson City, Nevada, USA
Founded
1970
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was $3.73. Over the last year, Anavex Life Sciences shares have traded in a share price range of $ 3.25 to $ 10.45.

Anavex Life Sciences currently has 82,112,511 shares outstanding. The market capitalization of Anavex Life Sciences is $319.42 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -6.72.

AVXL Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Anavex Life Sciences Announces Expansion of Leadership Team

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

May 22 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

May 17 2024
Edgar (US Regulatory)

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

May 14 2024
GlobeNewswire Inc.

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...

May 10 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 09 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 09 2024
Edgar (US Regulatory)

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

May 09 2024
GlobeNewswire Inc.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders PR Newswire NEW YORK, May 7, 2024 NEW YORK, May 7, 2024...

May 07 2024
PR Newswire (US)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 06 2024
Edgar (US Regulatory)

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.43M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.32M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.95M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

AVXL Discussion

View Posts
Investor2014 Investor2014 57 minutes ago
You make it sound like a competition of who can stand waiting the longest for Missling catalyst.

But of course the longer you wait the sooner you’ll get rich, but maybe only asymptotically so…
👍️0
Rubyred77 Rubyred77 2 hours ago
The resident idiot posting things we all already knew was going to happen because the ceo mentioned it earlier.

You deserve a day off bro.

👍️0
powerwalker powerwalker 3 hours ago
Wife wants to know if any discussion on:

1) Australia
2) Rare disease
3) Timeline on post-MAA filing

took place?

TIA
👍️0
k9uwa k9uwa 4 hours ago
Hi Tom I agree. We will be stuck for some time to come. Today's ASM firmed up a few things. No Exact dates of course. It was interesting how the volume picked up near the end of today. Also looks like a 200K BUY MOC. I think the Tutes are still buying. We won't know the answer to that until 15th of August... crazy that they get 45 days after the end of each quarter before they have to file their 13 F/D/G forms. I think they should have to file monthly and do it on the 15th of each month. Two Cents More on my stink bid for today and I would have had a few more shares. I put the bid in at $3.61. should have put 3.63 and most likely the bid would have been filled. Yes I have enough shares. But $3.63 would have slightly lowered my average cost per share.
Working on building great grandkids College funding. Pretty sure back in 2015 I picked the right horse for this race.
John k9uwa
🆖 1 💩 2
powerwalker powerwalker 5 hours ago
… or be gone for good, like many of us here.
🆖 1 💩 1
tredenwater2 tredenwater2 5 hours ago
I agree, hard facts are always desired. Just make a deal with yourself to give it until the end of the year, if you dont see an MAA filed you can go back to ranting and raving towards management.
🆖 1 💩 1
sumbuysumsell sumbuysumsell 5 hours ago
Right. I'm negative because I think talk is cheap and want to see some hard action. Gotcha. You go on and keep living the dream.
🎯 1 🏆️ 1 👋 1 👍️ 1 💩 2 🦨 2
tredenwater2 tredenwater2 5 hours ago
Someone has to counter all your negativity. If someone or something caused me the amount of grief you share I would drop them in a hot second. Why are you torturing yourself and others here? Smile, it just may change your day.
🆖 1 🍼 1 👍️ 2
tredenwater2 tredenwater2 5 hours ago
Thank you hnbadger for sharing/finding all this good news surrounding the ASM meeting. We need light to dispel the darkness. We should all be thankful and show gratitude for what we have instead of complaining about what we or others are lacking. Feelings of greed, anger, resentment, jealousy are all the work of ol hairy legs. Turn away and rejoice.

#WGT

Tred
🆖 1 🍼 1 👍️ 1
sumbuysumsell sumbuysumsell 5 hours ago
Not angry enough
Whelp. Someday the diehard members of the WGT cult may just start feeling like a mushroom. Until then it's all kumbaya nonsense. Anyone caught complaining gets on the ridiculous fudster listing and fish slapped.
🎯 1 🏆️ 1 👍️ 1 💩 1 🦨 1
meds4life meds4life 6 hours ago
re: shareholder tone/demeanour at ASM meeting
Not angry enough ( about no actions in support of cratered market cap/share price, missing their own timelines despite having expanded/expanding workforce, poorly constructed Rett trial requiring a do-over, LONG delays in sharing detailed results after trial completion, company opposition to letting shareholders provide feedback (NON-BINDING even) about increases in pay packages they vote to give themselves, about very low participation by them in owning/investing in AVXL shares, etc )
🆖 1 🍼 1 💩 1 🤡 1 🦨 1
kund kund 6 hours ago
Wrong again, the stock will go down on Thursday. People will digest the ASM news and realize that 2024 is another wasted year with nothing happening for the next six months. It's the same old kick-the-can strategy.
💩 1 🦨 1
georgejjl georgejjl 7 hours ago
CORRECTION!!!

The price of AVXL should increase on Thursday 20 June 2024 when it begins to trade based on the after hour trading pattern today,

Good luck and GOD bless,
🆖 1 💩 1
kund kund 7 hours ago
Misleading isn't publishing the AD full data or peer review because he knows that as soon as that data comes out, the stock will tank by 50%. The data will have bigger holes and will be taken to the shredder, just like his odds ratio.
🐀 2 👺 1 💩 1 🤡 1 🦨 1
georgejjl georgejjl 7 hours ago
The price of AVXL should increase on Wednesday 20 June 2024 when it begins to trade based on the after hour trading pattern today,

https://www.nasdaq.com/market-activity/stocks/avxl/after-hours-trades

Good luck and GOD bless,
🆖 1 💩 1
kund kund 7 hours ago
The clown is planning to run another Rett trial, but bigger this time (not necessarily better design). You're looking at 2030 for the Rett data readout. Just another kick-the-can strategy to string along WGT. Ten years and still no NDA submission, no approvable data—just "soon" and "around the corner" timelines.
🐀 2 👺 1 💩 1 🤡 1 🦨 1
k9uwa k9uwa 8 hours ago
"I predict the market will be flat tomorrow" Almost all of us agree on that statement. All except TotallJones he thinks we will go down tomorrow.
John k9uwa
🆖 1 💩 1 🤣 1
123tom 123tom 8 hours ago
It's a key battle zone for the price here at 3.75 area, support has been holding at critical support around 3.60/3.65 and now we get to watch what strength or weakness resistance has around 3.85/3.95. Anything can happen in this uncertain zone. Resistance continues every step to 4.00/4.05/4.10/4.15/4.20 and could turn right around and tumble down again. So I'm not seeing any decisive clues here yet, while there's still 7 trading days to end of June. Will some index and hedge funds dump shares next week.
🆖 1 🍼 1 🏁 1 👍️ 2
hnbadger1 hnbadger1 8 hours ago
More SHM notes from stjernerogvann on stock twits-
1. CM said we should assume by YE for MAA filing...but CM also suggested that was a CYA date. FWIW, 07SEP2024 should be around the date of filing if we follow the regulatory timeline breadcrumbs.
2. CM said the paper that will be released will make us happy. Great data across the board (endpoints, biomarkers, MRI) and we will be happy with the dose dependency, too.
3. OLE info will be a key component to the filings.
4. There is a Rett conference this week and something should be announced there (probably regarding new trial.)
5. The new Rett trial will be 2x as large as the last trial, will have a larger % of placebo patients, and the inclusion/exclusion criteria will be slightly modified based on lessons-learned.
🆖 1 🍼 1 👍️ 11 💥 1 💯 1
123tom 123tom 8 hours ago
I predict the market will be flat tomorrow. 🎱
🆖 1 👍️ 1 💩 2 🙂 1
ohsaycanyousee82 ohsaycanyousee82 8 hours ago
George? Is that you? Working in concert like a symphony!

Are we witnessing the partnership in action?
👍️ 2 🤣 1
BDR10 BDR10 8 hours ago
First of all the stock price stinks second of all there was no great news at all and third of all since you talking about predictions, how about about 500 of them that never came true
🎯 2 🏆️ 1 🐀 1 👍️ 1 👺 1 💩 1 🦨 1
georgejjl georgejjl 9 hours ago
ABSOLUTELY GREAT NEWS regarding Anavex just as predicted.

Good luck and GOD bless,
🆖 1 💩 2 🤡 1
kund kund 9 hours ago
Misleading snake oil salesman did it again.

Another update from ST


1. CM said we should assume by YE for MAA filing...but CM also suggested that was a CYA date. FWIW, 07SEP2024 should be around the date of filing if we follow the regulatory timeline breadcrumbs.
2. CM said the paper that will be released will make us happy. Great data across the board (endpoints, biomarkers, MRI) and we will be happy with the dose dependency, too.
3. OLE info will be a key component to the filings.
4. There is a Rett conference this week and something should be announced there (probably regarding new trial.)
5. The new Rett trial will be 2x as large as the last trial, will have a larger % of placebo patients, and the inclusion/exclusion criteria will be slightly modified based on lessons-learned.

This sounds similar to what he said at the last ASM: "Hope you will understand why we did the way we did." The guy is just kicking the can down the road. Peer review is another gimmick he has pulled.
🐀 1 👍️ 1 👺 1 💩 1 🤡 1 🦨 1
BDR10 BDR10 9 hours ago
Well Mr great news got embarrassed again, but we did get the usual missling word salad
🎯 1 🏆️ 1 🐀 1 👍️ 1 👺 1 💩 1 🦨 1
jav0033 jav0033 9 hours ago
Already down after hours back to $3.70

Shorts don’t care about juneteenth
🐀 1 👺 1 💩 1 🦨 1
tredenwater2 tredenwater2 9 hours ago
Thank you Ihid. Great stuff!
🆖 1 🍼 1 🏆️ 1 👍️ 3 💥 1
tredenwater2 tredenwater2 10 hours ago
Skimmed the beginning of this thesis. Looks like named shorting isnt so random.

From the GME board:

DR_rugby

https://www.researchgate.net/profile/Daniel-Pastorek/publication/369197965_Confirmation_of_T35_Failures-To-Deliver_Cycles_Evidence_from_GameStop_Corp/links/641054b666f8522c38a46501/Confirmation-of-T-35-Failures-To-Deliver-Cycles-Evidence-from-GameStop-Corp.pdf?origin=publication_detail&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InB1YmxpY2F0aW9uIiwicGFnZSI6InB1YmxpY2F0aW9uRG93bmxvYWQiLCJwcmV2aW91c1BhZ2UiOiJwdWJsaWNhdGlvbiJ9fQ
🆖 1 🏆️ 1 👍️ 1 💩 1
jav0033 jav0033 10 hours ago
LMAO.

I
See
What
You
Did
There!!

Shorts would’ve taken down to $3.68 with 100k volume
🐀 1 👺 1 💩 1 🦨 1
IhidfromtheX IhidfromtheX 10 hours ago
Tred...just for your knowledge...This is why I selected Apigenin for my cancer when I failed Chemo and two small tumors appeared, one in the lung and one in the liver along with the large tumor in the liver.. The two small ones vanished and the large stabilized making me elegible for Proton Therapy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207605/
🆖 1 🍀 1 🍼 1 👍️ 1
tredenwater2 tredenwater2 10 hours ago
Interesting read, thanks George. I forwarded the info to a friend whose mom has Alzheimer’s. I will look deeper into taking it myself as well for a few different conditions I see listed.

Cheers

Tred
🆖 1 👍️ 2 💩 1
georgejjl georgejjl 10 hours ago
Within the next week expect Part A of the phase 2 Anavex 3-71 schizophrenia will be completed and that the entire phase 2 Anavex 3-71 schizophrenia trial will be completed before the end of summer 2024.

There are approximately 24 million people worldwide who have schizophrenia.

https://www.anavex.com/_files/ugd/850d88_80ed72201c1f4173a87f87a09470aa46.pdf

Good luck and GOD bless,
🇺🇲
🆖 1 🍼 2 👍️ 2 👏 2
georgejjl georgejjl 10 hours ago
"...Intermittent fasting is a possible way to induce autophagy. Under normal conditions, when the cell has sufficient nutrients, autophagy degrades damaged components in the cell. When fasting starves the cells, autophagy helps digest some of the cell components, to provide the necessary energy for survival...."

https://www.medicinenet.com/how_long_do_you_need_to_fast_for_autophagy/article.htm

Good luck and GOD bless,
🆖 1 👍️ 1 💩 1
georgejjl georgejjl 10 hours ago
“The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer’s”.

https://www.anavex.com/post/anavex-life-sciences-reports-the-mechanism-of-anavex-2-73-blarcamesine-and-anavex-3-71-af710b

Good luck and GOD bless,
🆖 1 💩 1
ignatiusrielly35 ignatiusrielly35 10 hours ago
You repeated exactly what I said. Your distinction between a fund manager and an analyst is semantic. A fund manager is above an analyst, and makes the decisions.
🏆️ 1 👍️ 1
georgejjl georgejjl 10 hours ago
"...Starvation-induced autophagy was proven to be causal to lifespan extension in several animal models from yeasts to great apes (65, 66). Moreover, direct inhibition with rapamycin of the mTOR kinase, a master nutrient-sensing regulator of autophagy, systematically increased the median and maximum lifespan of mice...."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807614/#:~:text=Starvation%2Dinduced%20autophagy%20was%20proven,lifespan%20of%20mice%20(60).

"...Comparison of possible binding modes of Anavex2-73 to that of rapamycin..."

https://www.biotechtoinvest.com/research/2022/5/15/the-answer-was-here-all-the-time-why-anavex2-73-can-stop-alzheimers-disease

Good luck and GOD bless,
🆖 1 👍️ 3 💩 1
BDR10 BDR10 10 hours ago
Would that be after maybe another 50 tries of great news?
🎯 1 🏆️ 1 🐀 1 👺 1 💩 1 🦨 1
tredenwater2 tredenwater2 10 hours ago
“ Except, what’s “eaten” in cellular autophagy are the wastes and toxins that are self-produced by diseased cells. Eliminate those and cellular processes can continue normally, in good health.”

The only other way to “trigger” autophagy is to fast from food. The longer you fast the greater Autophagy that takes place as the body scavengers for energy and ends up burning the bad cells in the process.

I wonder if this has an impact on weight loss with a proper diet? As diet and gut health improve so does mitochondrial dysfunction.

“Mitochondrial disease can cause a vast array of health concerns, including fatigue, weakness, metabolic strokes, seizures, cardiomyopathy, arrhythmias, developmental or cognitive disabilities, diabetes mellitus, impairment of hearing, vision, growth, liver, gastrointestinal, or kidney function, and more.”

https://www.chop.edu › mitochon...

Cheers!

Tred
🆖 1 🍼 1 🏁 1 👍️ 4 💥 1
WilliamMunny WilliamMunny 11 hours ago
I listened to her call, Hosai. It seemed that she wanted to, hopefully, demonstrate that the Annovis drug could ameliorate symptoms, like Aricept does, over a six month period, but then have ongoing disease modification effects - the best of both world. I have never been invested in that and certainly am not the best qualified to comment, but that seems to be the thrust of the trial. The company is pretty much out of cash, and this is a big trial being proposed, so getting the necessary financing would seem to be an extremely dilutive undertaking.
🆖 1 👍️ 2 💩 1
kund kund 11 hours ago
Misleading as usual, giving tidbits to the WGT crowd. Peer review looks to be a non-starter, another hogwash. EMA filing might be pushed to next year, and approval, if it comes, looks like 2026/2027. FDA filing? Probably never. Year 2024 is half gone, and the rest will be vacation. The PD trial was promised in February 2023, and 1.5 years later, they are still planning.
🐀 1 👺 1 💩 1 🤡 1 🦨 1
georgejjl georgejjl 11 hours ago
Happy Birthday Sir Paul!!!

Anavex's blarcamesine is headed for approval to treat Alzheimer's disease in the EU and the UK.

Good luck and GOD bless,
🆖 1 🏁 1 👍️ 1 💩 3
Talon38 Talon38 11 hours ago
A sad commentary on the early onset of Alzheimer's in Michael Irvin's wife. Every reason for the progress our drug as hope for them and many other couples fighting this terrible disease. Michael has his hope in God's providence, and we hope that God works thru Anavex and other fruitful research!

https://www.foxnews.com/sports/cowboys-legend-michael-irvin-reveals-wife-58-has-early-onset-alzheimers
🆖 1 🍼 1 🏁 1 👍️ 5 ♥️ 3 ❤️ 1
IhidfromtheX IhidfromtheX 11 hours ago
PMS completed on the CATS this morning....At the ready!
🆖 1 💩 1
nidan7500 nidan7500 11 hours ago
Thanks very much for the effort by all informed posters today. Bottom line...WGT..... but, only after many very smart people worked their guts out to guide us on this path. Prepare the flight deck for air operations.
🆖 1 🍼 1 🏁 1 👍️ 7 💯 2
IhidfromtheX IhidfromtheX 11 hours ago
So what you're saying is that....Certified financial analysts don't own shares in stock so they don't go to annual meetings?
🆖 1 👍️ 1 💩 1
BIOChecker4 BIOChecker4 12 hours ago
Fund managers of funds that own a position are allowed to attend annual meetings. You should learn the difference between certified financial analysts and fund managers.

BTW, I’m not trying to impress anybody. I’m simply stating a fact about how these things work based on my experience. Instead of getting your back up, you should listen more and talk less. You might even learn something.
🎯 1 🏆️ 1 🐀 1 👎️ 1 👺 2 💩 2 🦨 1
Hosai Hosai 12 hours ago
Annovis CEO wants to do an AD phase 3 which is an 18 month disease modification trial where the data is also taken at 6 months as a seperate 'disease modification' trial for which they would submit an NDA based just on these 6 months. Seems like this would be in danger of jeapordizing the overall 18 month trial? Even with the new FDA guidance 6 months seems too short.
🆖 1 👍️ 6 💩 1
mike_dotcom mike_dotcom 12 hours ago
I can guarantee you the stock WILL NOT go down tomorrow.
👍️ 3 😀 2 😃 1 😆 1 🙂 1
powerwalker powerwalker 12 hours ago
William, great summary and I love your last remark.

Looking forward to tomorrow’s Rett presentation.

Thanks Sgyp, William.

Peace
powerwalker
🆖 1 🍼 1 👍️ 8 💥 1
ignatiusrielly35 ignatiusrielly35 12 hours ago
Yeah, well I was stone where a fund manager of a leading biotech fund was present. His firm already had a large position. He did not ask questions but everyone knew who he was. I’m guessing he met with the CEO afterward. Chill out, Mr. Big Shot. You’re not impressing anybody.
🏆️ 2 👍️ 4 👏 2

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
NB
NioCorp Developments
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
SPZI
Spooz (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
RDGL
Vivos (QB)
NASDAQ
NVDA
NVIDIA
USOTC
BLLB
Bell Buckle (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
GGSM
Gold and GemStone Mining (PK)
USOTC
CBIA
Canopus Biopharma (PK)
NYSE
PFE
Pfizer
FTSE
UKX
FTSE 100
NYSE
TWTR
Twitter
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved